Medical device leader Cochlear has significantly lowered its fiscal 2026 net profit outlook, triggering a sharp decline in share price. The company cites reduced demand and currency headwinds as primary drivers for the revision.
- Net profit guidance cut to A$290-330 million
- Gross margin expected to drop by 1% due to production cuts
- H2 sales growth projected at 2-6% (constant currency)
- Share price collapsed by over 40%
- Company accelerating cost-base restructuring
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.